MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and...
TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on...
Patient with melanoma, having failed dual check-point inhibitor therapy, achieved a complete response following treatment with MDNA11 at week 52 with 100% regression of all target and non-target...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -4.8309178744 | 2.07 | 2.09 | 1.91 | 68033 | 2.02759018 | CS |
4 | -0.18 | -8.37209302326 | 2.15 | 2.62 | 1.91 | 59667 | 2.18087348 | CS |
12 | -0.05 | -2.47524752475 | 2.02 | 2.62 | 1.77 | 66391 | 2.11583674 | CS |
26 | 0.39 | 24.6835443038 | 1.58 | 2.98 | 1.4 | 119999 | 2.1165138 | CS |
52 | 1.57 | 392.5 | 0.4 | 2.98 | 0.215 | 103478 | 1.53560212 | CS |
156 | -1.16 | -37.0607028754 | 3.13 | 3.67 | 0.215 | 62281 | 1.50085503 | CS |
260 | 0.42 | 27.0967741935 | 1.55 | 7.25 | 0.215 | 74664 | 2.7297506 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.